Immune Design Corp. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 57 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-04-02: Reporting owner BERGER FRANKLIN M; Form 4; Security Stock Option (Rt to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2019-04-02: Reporting owner BERGER FRANKLIN M; Form 4; Security Stock Option (Rt to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2019-04-02: Reporting owner BERGER FRANKLIN M; Form 4; Security Stock Option (Rt to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2019-04-02: Reporting owner BALTIMORE DAVID; Form 4; Security Stock Option (Rt to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-04-02 | BERGER FRANKLIN M Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $5.60 exercise price | 2019-04-04 | |
| 2019-04-02 | BERGER FRANKLIN M Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | BERGER FRANKLIN M Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | BALTIMORE DAVID Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −3,058 0 owned after | $1.48 exercise price | 2019-04-04 | |
| 2019-04-02 | BALTIMORE DAVID Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −4,281 0 owned after | $1.23 exercise price | 2019-04-04 | |
| 2019-04-02 | BALTIMORE DAVID Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $5.60 exercise price | 2019-04-04 | |
| 2019-04-02 | BALTIMORE DAVID Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | BALTIMORE DAVID Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | Yurasov Sergey Officer (Sr. VP, Clinic. Devel. & CMO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −110,000 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | Yurasov Sergey Officer (Sr. VP, Clinic. Devel. & CMO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −113,335 0 owned after | $4.40 exercise price | 2019-04-04 | |
| 2019-04-02 | Yurasov Sergey Officer (Sr. VP, Clinic. Devel. & CMO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −110,000 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | Brady Stephen R Officer (EVP, Strategy & Finance) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −116,819 0 owned after | $1.23 exercise price | 2019-04-04 | |
| 2019-04-02 | Brady Stephen R Officer (EVP, Strategy & Finance) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −100,000 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | Brady Stephen R Officer (EVP, Strategy & Finance) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −184,364 0 owned after | $4.40 exercise price | 2019-04-04 | |
| 2019-04-02 | Brady Stephen R Officer (EVP, Strategy & Finance) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −120,000 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | Gombotz Wayne Officer (Chief Development Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −38,715 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | Gombotz Wayne Officer (Chief Development Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −6,116 0 owned after | $1.48 exercise price | 2019-04-04 | |
| 2019-04-02 | Gombotz Wayne Officer (Chief Development Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −40,697 0 owned after | $1.23 exercise price | 2019-04-04 | |
| 2019-04-02 | Gombotz Wayne Officer (Chief Development Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −32,083 0 owned after | $5.60 exercise price | 2019-04-04 | |
| 2019-04-02 | Gombotz Wayne Officer (Chief Development Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −11,407 0 owned after | $4.40 exercise price | 2019-04-04 | |
| 2019-04-02 | Paya Carlos V Director, Officer (President and CEO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −195,289 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | Paya Carlos V Director, Officer (President and CEO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −67,277 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | Paya Carlos V Director, Officer (President and CEO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −61,161 0 owned after | $1.48 exercise price | 2019-04-04 | |
| 2019-04-02 | Paya Carlos V Director, Officer (President and CEO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −244,648 0 owned after | $1.23 exercise price | 2019-04-04 | |
| 2019-04-02 | Paya Carlos V Director, Officer (President and CEO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −175,000 0 owned after | $5.60 exercise price | 2019-04-04 | |
| 2019-04-02 | Paya Carlos V Director, Officer (President and CEO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −216,500 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | Paya Carlos V Director, Officer (President and CEO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −263,009 0 owned after | $4.40 exercise price | 2019-04-04 | |
| 2019-04-02 | Paya Carlos V Director, Officer (President and CEO) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −293,000 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | ter Meulen Jan Henrik Officer (Chief Scientific Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −98,837 0 owned after | $1.23 exercise price | 2019-04-04 | |
| 2019-04-02 | ter Meulen Jan Henrik Officer (Chief Scientific Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −70,000 0 owned after | $5.60 exercise price | 2019-04-04 | |
| 2019-04-02 | ter Meulen Jan Henrik Officer (Chief Scientific Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −90,000 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | ter Meulen Jan Henrik Officer (Chief Scientific Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −46,788 0 owned after | $4.40 exercise price | 2019-04-04 | |
| 2019-04-02 | ter Meulen Jan Henrik Officer (Chief Scientific Officer) | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −120,000 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | Kelley Susan L. Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $5.60 exercise price | 2019-04-04 | |
| 2019-04-02 | Kelley Susan L. Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | Kelley Susan L. Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | PENHOET EDWARD Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −3,058 0 owned after | $1.48 exercise price | 2019-04-04 | |
| 2019-04-02 | PENHOET EDWARD Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −4,281 0 owned after | $1.23 exercise price | 2019-04-04 | |
| 2019-04-02 | PENHOET EDWARD Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $5.60 exercise price | 2019-04-04 | |
| 2019-04-02 | PENHOET EDWARD Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | PENHOET EDWARD Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | RINGO WILLIAM R Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $5.60 exercise price | 2019-04-04 | |
| 2019-04-02 | RINGO WILLIAM R Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | RINGO WILLIAM R Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-04-02 | COLEMAN LEWIS W Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −10,000 0 owned after | $5.60 exercise price | 2019-04-04 | |
| 2019-04-02 | COLEMAN LEWIS W Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $4.05 exercise price | 2019-04-04 | |
| 2019-04-02 | COLEMAN LEWIS W Director | 4 | Stock Option (Rt to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $1.31 exercise price | 2019-04-04 | |
| 2019-01-03 | Paya Carlos V Director, Officer (President and CEO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +293,000 293,000 owned after | $1.31 exercise price | 2019-01-07 | |
| 2019-01-03 | ter Meulen Jan Henrik Officer (Chief Scientific Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +120,000 120,000 owned after | $1.31 exercise price | 2019-01-07 | |
| 2019-01-03 | Yurasov Sergey Officer (Sr. VP, Clinic. Devel. & CMO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +110,000 110,000 owned after | $1.31 exercise price | 2019-01-07 | |
| 2019-01-03 | Brady Stephen R Officer (EVP, Strategy & Finance) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +120,000 120,000 owned after | $1.31 exercise price | 2019-01-07 | |
| 2019-01-03 | COLEMAN LEWIS W Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $1.31 exercise price | 2019-01-07 | |
| 2019-01-03 | RINGO WILLIAM R Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $1.31 exercise price | 2019-01-07 | |
| 2019-01-03 | BERGER FRANKLIN M Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $1.31 exercise price | 2019-01-07 | |
| 2019-01-03 | BALTIMORE DAVID Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $1.31 exercise price | 2019-01-07 | |
| 2019-01-03 | Kelley Susan L. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $1.31 exercise price | 2019-01-07 | |
| 2019-01-03 | PENHOET EDWARD Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $1.31 exercise price | 2019-01-07 |